Oculis Holding AG
NASDAQ:OCSBiotechnology
-$0.28 today
- Market cap
- $456.20M
- Beta
- 0.13
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.61
Volume 0.31M
Average 0.65M
OCS Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Oculis Holding AGNASDAQ: OCS
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares grows, but more slowly than its trailing trend
Q1 FY2026 weighted avg shares of 58.91M shares rose 22.1% year over year, behind the +27.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 5.2% from the prior quarter. Over 3 fiscal years it compounded at +16.9% a year.
Context
- Weighted avg shares increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +22.1% toward the trailing-twelve-month pace of +27.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 52.36M CHF
- Year-over-year change
- +29.6%
- 4-year CAGR
- +12.5%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 52.36M | +29.6% |
| FY2024 | 2024-12-31 | 40.41M | +35.1% |
| FY2023 | 2023-12-31 | 29.9M | -8.7% |
| FY2022 | 2022-12-31 | 32.73M | +0.0% |
| FY2021 | 2021-12-31 | 32.73M | — |
Weighted Avg Shares vs competitors
How OCS compares with its peers on the latest reported figures
- OCS's LTM Mar 2026 weighted avg shares of 54.96M shares is the 3rd highest of the 6 companies compared; the peer median is 53.45M shares.
- Its year-over-year change of +27.5% is the 4th highest of 6, against a peer median of +27.7%.
- Over three fiscal years its annual growth of +16.9% compares with a peer median of +34.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 200.88M | +19.9% | +34.5% | |
| LTM Mar 2026 | 77.28M | +27.7% | +25.2% | |
| LTM Mar 2026 | 54.96M | +27.5% | +16.9% | |
| LTM Mar 2026 | 53.45M | +120.6% | +48.6% | |
| FY2025 | 39.49M | +34.6% | +37.9% | |
| LTM Mar 2026 | 36.98M | +3.5% | +10.2% | |
| Peer median (excluding OCS) | 53.45M | +27.7% | +34.5% | |
Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 686K | 0 |
| Cost of Revenue | 0 | 0 | 0 | 52.08M | 0 |
| Gross Profit | 0 | 0 | 0 | (51.4M) | 0 |
| Gross Margin | — | — | — | -7492.3% | — |
| Research & Development | 9.57M | 22.22M | 29.25M | 52.08M | 54.52M |
| Selling, General & Admin | 4.1M | 6.74M | 14.72M | 21.81M | 24.63M |
| Operating Expenses | 13.23M | 32.38M | 80.71M | 21.81M | 79.15M |
| Depreciation & Amortization | 235K | 299K | 287K | 406K | 521.45K |
| EBITDA | (13.17M) | (31.9M) | (87.09M) | (85.53M) | (93.37M) |
| EBITDA Margin | — | — | — | -12468.1% | — |
| Operating Income | (13.23M) | (32.38M) | (80.71M) | (73.2M) | (79.15M) |
| Operating Margin | — | — | — | -10671.1% | — |
| Interest Income | 21K | 126K | 1.59M | 2.17M | 1.69M |
| Interest Expense | 5.12M | 6.44M | 1.46M | 639K | 795.55K |
| Other Income / Expenses | (5.29M) | (6.27M) | (7.98M) | (12.73M) | (15.54M) |
| Income Before Tax | (18.52M) | (38.64M) | (88.7M) | (85.94M) | (94.69M) |
| Pre-Tax Margin | — | — | — | -12527.3% | — |
| Income Tax Expense | 27K | 55K | 107K | (160K) | 177.64K |
| Net Income | (18.55M) | (38.7M) | (88.8M) | (85.78M) | (94.51M) |
| Net Margin | — | — | — | -12503.9% | — |
| EPS (Basic) | (0.57) | (1.18) | (2.97) | (2.12) | (1.81) |
| EPS (Diluted) | (0.57) | (1.18) | (2.97) | (2.12) | (1.81) |
| Weighted Avg Shares | 32.73M | 32.73M | 29.9M | 40.41M | 52.36M |
| Weighted Avg Shares (Diluted) | 32.73M | 32.73M | 29.9M | 40.41M | 52.36M |
Oculis Holding AG
NASDAQ:OCS
Intrinsic Alpha fair value
Locked
Current Price
$7.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.